ClinicalTrials.gg
Active, not recruitingNCT04077099Updated Sep 16, 2026

A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer

A Phase 1/2 interventional study of REGN5093 in NSCLC, sponsored by Regeneron Pharmaceuticals. Active, not recruiting at 29 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-16.

Sponsored by Regeneron Pharmaceuticals · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
95
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Carcinoma, Non-Small-Cell Lung by Regeneron Pharmaceuticals — 2 open to participants now, 11 under way, 2 of them phase 3. Carcinoma, Non-Small-Cell Lung · Regeneron Pharmaceuticals.

Enrollment
9th of 18
95 · median 86
Started
2020
the only one that year
Phase 1/2
3 of 21
1 open now
Primary completion
2027-07
later than 3 of 10 live
Registered
9th of 21
by date

Among the 21 studies in Carcinoma, Non-Small-Cell Lung by Regeneron Pharmaceuticals, this one is the 9th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2020, is one of 3 in phase 1/2, reaches primary completion later than 3 of the 10 other live ones, and was the 9th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

2 of the 21 studies in Carcinoma, Non-Small-Cell Lung by Regeneron Pharmaceuticals are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Carcinoma, Non-Small-Cell Lung by Regeneron Pharmaceuticals, or all of them as a file.
02

Study summary

This study will evaluate REGN5093 for the treatment of Non-Small Cell Lung Cancer (NSCLC) with MET alteration. The main purpose of this study is to determine the safety, tolerability, and effectiveness of REGN5093.

The study has two phases. The main goal of Phase 1 is to determine a safe dose(s) of REGN5093. The main goal of phase 2 of the study is to use the REGN5093 drug dose(s) found in Phase 1 to see how well REGN5093 works to shrink tumors.

The study is looking at several other research questions, including:

  • Side effects that may be experienced by people taking REGN5093
  • How REGN5093 works in the body
  • How much REGN5093 is present in the blood
  • To see if REGN5093 works to reduce or delay the progression of cancer
  • How long it takes REGN5093 to work in the body
03

Conditions studied

  • NSCLC

Keywords

  • MET (mesenchymal-epithelial transition factor)
  • HGF (Hepatocyte Growth Factor)
  • NSCLC (non-small cell lung cancer)
  • MET-altered advanced
  • Unresectable
  • Metastatic disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. confirmed advanced NSCLC that is unresectable or as described in the protocol
  2. Willing to provide tumor tissue as described in the protocol
  3. Documented presence of MET alteration as described in the protocol.
  4. (ECOG) performance status of 0 or 1
  5. Adequate organ and bone marrow function as described in the protocol

Key Exclusion Criteria:

  1. Has received treatment with an approved systemic therapy or has participated in any study of an agent or investigational device within 2 weeks as described in the protocol
  2. Has not yet recovered from any acute toxicities resulting from prior therapy with certain exceptions as described in the protocol
  3. Has received radiation therapy or major surgery within 14 days as described in the protocol
  4. Untreated or active primary brain tumor, central nervous system (CNS) metastases, or spinal cord compression as defined in the protocol
  5. Uncontrolled infection as described in the protocol

Note: Other protocol defined Inclusion/Exclusion criteria apply

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
95 participants (actual)

Study arms

  • Experimental
    REGN5093

    Monotherapy in dose escalation cohorts (phase 1) followed by an expansion phase (phase 2)

    Drug: REGN5093

Interventions

  • DrugREGN5093

    Intravenous (IV) infusion. There will be a series of dose escalation cohorts followed by an expansion phase.

    Also known as: davutamig

06

What researchers measure

Primary outcomes

  1. Number of patients with Dose Limiting Toxicities (DLTs)

    Phase 1/Dose escalation

    Time frame: Up to 21 days

  2. Incidence and severity of treatment-emergent adverse events (TEAEs)

    Phase 1/Dose escalation

    Time frame: Through study completion, an average of 12 years

  3. Incidence and severity of adverse events of special interest (AESIs)

    Phase 1/Dose escalation

    Time frame: Through study completion, an average of 12 years

  4. Incidence and severity of serious adverse events (SAEs)

    Phase 1/Dose escalation

    Time frame: Through study completion, an average of 12 years

  5. Incidence and severity of grade ≥3 laboratory abnormalities

    Phase 1/Dose escalation

    Time frame: Through study completion, an average of 12 years

  6. REGN5093 concentrations in serum over time

    Phase 1/Dose escalation

    Time frame: Through study completion, an average of 12 years

  7. Objective response rate (ORR) per RECIST 1.1

    Phase 2/Dose expansion

    Time frame: Through study completion, an average of 12 years

Secondary outcomes

  1. ORR per RECIST 1.1

    Phase 1/Dose escalation

    Time frame: Through study completion, an average of 12 years

  2. Incidence and severity of TEAEs

    Phase 2/Dose expansion

    Time frame: Through study completion, an average of 12 years

  3. Incidence and severity of AESIs

    Phase 2/Dose expansion

    Time frame: Through study completion, an average of 12 years

  4. Incidence and severity of SAEs

    Phase 2/Dose expansion

    Time frame: Through study completion, an average of 12 years

  5. Incidence and severity of grade ≥3 laboratory abnormalities

    Phase 2/Dose expansion

    Time frame: Through study completion, an average of 12 years

  6. REGN5093 Pharmacokinetics (PK)

    Phase 2/Dose expansion

    Time frame: Through study completion, an average of 12 years

  7. REGN5093 concentrations in serum over time

    Phase 2/Dose expansion

    Time frame: Through study completion, an average of 12 years

  8. Duration of response (DOR) per RECIST 1.1.

    Phase 1 and 2

    Time frame: Through study completion, an average of 12 years

  9. Disease control rate (DCR) per RECIST 1.1.

    Phase 1 and 2

    Time frame: Through study completion, an average of 12 years

  10. Progression free survival (PFS) per RECIST 1.1.

    Phase 1 and 2

    Time frame: Through study completion, an average of 12 years

  11. Overall survival (OS)

    Phase 1 and 2

    Time frame: Through study completion, an average of 12 years

  12. Time to response (TTR) per RECIST 1.1

    Phase 1 and 2

    Time frame: Through study completion, an average of 12 years

  13. Incidence of anti-drug antibodies (ADA) to REGN5093

    Phase 1 and 2

    Time frame: Through study completion, an average of 12 years

  14. Titer of ADA to REGN5093

    Phase 1 and 2

    Time frame: Through study completion, an average of 12 years

07

Study locations

29 sites
08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) has the legal authority to share the data, and has ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2020 (actual). Primary completion is estimated for Jul 2027, 89 months after the start.

Of 312 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's planned 89 months is above that.

Counting every sponsor, half of 436 studies reached it within 63 months; a quarter within 41 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2019
First posted
Sep 4, 2019
StartActual
Jan 7, 2020
Primary completionEst.
Jul 6, 2027
CompletionEst.
Jul 6, 2027
Last update
Sep 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04077099
Responsible party
Sponsor
First posted
Sep 4, 2019
Start date
Jan 7, 2020
Primary completion
Jul 6, 2027 (estimated)
Completion
Jul 6, 2027 (estimated)
Last update
Sep 16, 2026

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion